个人简介

博士生导师，课题组长。长期从事生物材料及技术用于恶性肿瘤治疗研究，包括肿瘤智能药物递送新技术和创新制剂的研发，并重点围绕抗肿瘤原创药物的合成、纳米药物制剂化及应用等领域开展研究工作，创建了独具个人研究特色的前药策略，取得了一系列重要的原创性科研成果，已在J. Am. Chem. Soc.、Angew. Chem. Int. Ed.、Cancer Res.、Nano Today、Adv. Funct. Mater.、J. Controlled Release、Nucleic Acids Res.、ACS Nano 等高水平学术期刊以第一或通讯作者发表研究论文60多篇。以第一发明人获得15 项中国发明专利授权。作为项目负责人获得3项国家自然科学基金面上项目和1项青年项目，并获得2018年浙江省自然科学基金杰出青年项目的资助。

专业擅长

针对恶性肿瘤及各种临床疾病设计合成药物及纳米制剂。

研究方向

主要聚焦于肝胆胰疾病的药物治疗研究，抗癌创新药物、纳米药物递送以及抗癌分子机制的研究。

成果奖项：（近五年主要成果及奖励情况）

近五年代表论文：

1) Quantitative Self-Assembly of Photoactivatable Small Molecular Prodrug Cocktails for Safe and Potent Cancer Chemo-Photodynamic Therapy, L. Huang, J. Wan, H. Wu, X. Chen, Q. Bian, L. Shi, X. Jiang, A. Yuan, J. Gao*, and H. Wang*, Nano Today, 2021, 36, 101030.

2) 2) Self-assembling a natural small molecular inhibitor that shows aggregation-induced emission and potentiates antitumor efficacy, X. Chen, Z. Hu, L. Zhou, F. Zhang, J. Wan, and H. Wang*, Nanoscale Horizons, 2021, 6, 33-42.

3) Structure-Guided Engineering of Cytotoxic Cabazitaxel for an Adaptive Nanoparticle Formulation: Enhancing the Drug Safety and Therapeutic Efficacy, J. Wan, Y. Qiao, X. Chen, J. Wu, L. Zhou, J. Zhang, S. Fang and H. Wang*, Adv. Funct. Mater., 2018, 28, 1804229.

4) Self-assembling prodrugs by precise programming of molecular structures that contribute distinct stability, pharmacokinetics, and antitumor efficacy, H. Wang, H. Xie, J. Wang, J. Wu, X. Ma, L. Li, X. Wei, Q. Ling, P. Song, L. Zhou, X. Xu,* and S. Zheng*, Adv. Funct. Mater., 2015, 25, 4956-4965.

5) New Generation Nanomedicines Constructed from Self-Assembling Small Molecule Prodrugs Alleviate Cancer Drug Toxicity, H. Wang*, Z. Lu, L. Wang, T. Guo, J. Wu, Z. Li, D. Jiang, P. Song, H. Xie, L. Zhou, X. Xu and S. Zheng*, Cancer Res., 2017, 77, 6963-6974.

6) Design and fabrication of conductive polymer hydrogels and their applications in flexible supercapacitors, X Han, G. Xiao*, Y. Wang, X. Chen, G. Duan, Y. Wu, X. Gong*, and H. Wang*, J. Mater. Chem. A, 2020, 8, 23059-23095.

7) Quantum dots-based hydrogels for sensing applications, J. Zhang, J. Jin, J. Wan, S. Jiang, W. Wang, X. Gong*, and H. Wang*, Chemical Engineering Journal, 2021, 408, 127351.

8) Target-Oriented Delivery of Self-Assembled Immunosuppressant Cocktails Prolongs Allogeneic Orthotopic Liver Transplant Survival, H. Xie,# H. Zhu,# K. Zhou, J. Wan, L. Zhang, Z. Yang, L. Zhou, X. Chen, X. Xu, S. Zheng,* and H. Wang*, J. Controlled Release, 2020, 328, 237-250.

9) Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts, L. Shi, Y. Wang, Q. Wang, Z. Jiang, L. Ren, Y. Yan, Z. Liu, J. Wan, L. Huang, B. Cen, W. Han*, and H. Wang*, J. Controlled Release, 2020, 324, 289-302.

10) Photosensitizer-stabilized self-assembling nanoparticles potentiate chemo/photodynamic efficacy of patient-derived melanoma, L. Huang, X. Chen, Q. Bian, F. Zhang, H. Wu, H. Wang*, and J. Gao*, J. Controlled Release, 2020, 328, 325-338.

11) Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery Platforms for enhanced antitumor efficacy, H. Wang*, H. Xie, J. Wu, X. Wei, L. Zhou, X. Xu,* and S. Zheng*, Angew. Chem. Int. Ed., 2014, 53, 11532-11537.

12) Self-assembling myristoylated human alpha-defensin 5 as a next-generation nanobiotics potentiates therapeutic efficacy in bacterial infection, R. Lei, J. Hou, Q. Chen, W. Yuan, B. Cheng, Y. Sun, Y. Jin, L. Ge, S. A. Ben-Sasson, H. Wang*, W. Lu*, X. Fang*, ACS Nano, 2018, 12, 5284-5296.

13) ZNF830 Mediates Cancer Chemoresistance through Promoting Homologous-Recombination Repair, G. Chen*, J. Chen, Y. Qiao, Y. Shi, W. Liu, Q. Zeng, X. Shi, Y. Sun, X. Liu, T. Li, L. Zhou, J. Wan, H. Wang* and F. Wang*, Nucleic Acids Res., 2018, 46, 1266-1279.

14) A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer, W. Han, L. Shi, T. Li, L. Zhou, L. Ren, Y. Qiao and H. Wang*, Signal Transduction and Targeted Therapy, 2018, 3, 16.

15) Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer, W. Han*, B. Xie, Y. Li, L. Shi, J. Wan, X. Chen and H. Wang*, Theranostics, 2019, 9, 7458-7473.

16) Polylactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma, H. Wang*, L. Zhou, K. Xie, J. Wu, P. Song, H. Xie, L. Zhou, J. Liu, X. Xu, Y. Shen and S. Zheng*, Theranostics, 2018, 8, 3949-3963.

17) Cancer Nanomedicines Stabilized by π-π Stacking between Heterodimeric Prodrugs Enable Exceptionally High Drug Loading Capacity and Safer Delivery of Drug Combinations, H. Wang*, J. Chen, C. Xu, M. Tayier, J. Zhou, J. Zhang, J. Wu, Z. Ye, T. Fang, W. Han*, Theranostics, 2017, 7, 3638-3652.

18) Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma, L. Wu, F. Zhang, X. Chen, J. Wan, Y. Wang, T. Li, and H. Wang*, ACS Applied Materials & Interfaces, 2020, 12, 3327-3340.

19) Supramolecular Engineering of Molecular Inhibitors in an Adaptive Cytotoxic Nanoparticle for Synergistic Cancer Therapy, W. Han*, L. Shi, B. Xie, J. Wan, L. Ren, Y. Wang, X. Chen and H. Wang*, ACS Applied Materials & Interfaces, 2020, 12, 1707-1720.

20) Precise Engineering of Prodrug Cocktails into Single Polymeric Nanoparticles for Combination Cancer Therapy: Extented and Sequentially Controllable Drug Release, H. Wang*, J. Wu, K. Xie, T. Fang*, C. Chen, H. Xie. L. Zhou, and S. Zheng*, ACS App. Mater. & Interfaces, 2017, 9, 10567-10576.

21) Dimerization-Induced Self-Assembly of a Redox-Responsive Prodrug into Nanoparticles for Improved Therapeutic Index, L. Zhou, H. Xie, X. Chen, J. Wan, S. Xu, Y. Han, D. Chen, Y. Qiao, L. Zhou, S. Zheng*, and H. Wang*, Acta Biomaterialia, 2020, 113, 464-477.

22) Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies, B. Xie, J. Wan, X. Chen, W. Han* and H. Wang*, Mol. Cancer Ther., 2020, 19, 822-834.

社会任职

担任浙江省药学会生物制药专业委员会青年分委会副主任委员

SCI期刊Chinese Chemical Letters的青年编委